Skip to main content
    K

    Kymera Therapeutics Inc (KYMR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $125.85
    -1.72 (-1.35%)

    Market Cap: $10.89B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Kymera Therapeutics Inc (KYMR) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Kymera Therapeutics (KYMR) to earn -$3.93 per share in the fiscal year ending Dec 31, 2026, on revenue of $99.39M. Of 24 analysts, 22 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 8 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 24 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.

    RatingAnalystsShare
    Strong Buy520.8%
    Buy1770.8%
    Hold28.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    24

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 57.7%.

    Fiscal year ending Dec 31, 2026
    -$3.93
    EPS consensus, revenue $99.39M
    Fiscal year ending Dec 31, 2027
    -$5.12
    EPS consensus, revenue $42.03M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$3.93-$4.21 to -$3.1322$99.39M$98.00M to $101.40M21
    Dec 31, 2027-$5.12-$6.70 to -$3.3622$42.03MN/A23

    Quarterly Estimates

    The EPS consensus falls from -$1.33 for the quarter ending Dec 31, 2026 to -$1.35 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.33-$1.51 to -$0.8227$545986N/A24
    Mar 31, 2027-$1.35-$1.52 to -$1.087$7.00MN/A6

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 8 upward and 16 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202628
    Fiscal year ending Dec 31, 202757
    Quarter ending Mar 31, 202711

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.51.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$3.93-$3.85-$3.84-$3.78-$3.51N/A
    Fiscal year ending Dec 31, 2027-$5.12-$5.10-$5.10-$4.94-$4.36N/A
    Quarter ending Mar 31, 2027-$1.35-$1.36-$1.36-$1.26-$1.06N/A

    Frequently Asked Questions About KYMR

    What is the KYMR stock forecast?

    Consensus analyst estimates put Kymera Therapeutics's EPS at -$3.93 for the fiscal year ending Dec 31, 2026, on revenue of $99.39M. The consensus rating from 24 analysts is Buy.

    How do analysts rate KYMR stock?

    Of 24 analysts covering Kymera Therapeutics, 5 rate it Strong Buy, 17 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from KYMR next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.93, with estimates from -$4.21 to -$3.13 from 22 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$5.12, with estimates from -$6.70 to -$3.36 from 22 analysts.

    What revenue do analysts expect from Kymera Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $99.39M, with estimates from $98.00M to $101.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $42.03M.

    How many analysts cover KYMR?

    24 analysts rate Kymera Therapeutics stock, and 22 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.